Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/2013
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lawrentschuk, Nathan | - |
dc.contributor.author | Heriot, Alexander | - |
dc.contributor.other | Teh, Jiasian | - |
dc.contributor.other | O'Connor, Ellen | - |
dc.contributor.other | O'Brien, Jonathan | - |
dc.contributor.other | Lim, Wei Mou | - |
dc.contributor.other | Taylor, Michael | - |
dc.contributor.other | Ramsay, Robert | - |
dc.date.accessioned | 2021-07-30T03:26:42Z | - |
dc.date.available | 2021-07-30T03:26:42Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.citation | Future Oncol . 2020 Oct;16(29):2357-2369 | en_US |
dc.identifier.issn | 1744-8301 | en_US |
dc.identifier.issn | 1479-6694 | en_US |
dc.identifier.uri | http://hdl.handle.net/11434/2013 | - |
dc.description.abstract | Penile squamous cell carcinoma (SCC) is a rare and aggressive urological malignancy. Advanced penile SCC requires multimodal management, including surgery and systemic therapy. Given its rarity, there have been few substantial advances in our understanding of the molecular and genomic drivers of penile SCC, especially for patients with relapsed or advanced disease. In this review, we discuss the molecular and genomic landscape of penile SCC, clinical trials in progress and implications for novel therapeutic targets. Future work should focus on preclinical models to provide a platform for investigation and validation of new molecular pathways for testing of therapeutics. | en_US |
dc.publisher | Future Medicine | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Pathogenesis | en_US |
dc.subject | Penile Cancer | en_US |
dc.subject | Solid Tumor | en_US |
dc.subject | Squamous Cell Carcinoma | en_US |
dc.subject | Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia | en_US |
dc.subject | Urology and Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia | en_US |
dc.title | Future directions in advanced penile cancer - mechanisms of carcinogenesis and a search for targeted therapy. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.2217/fon-2020-0434 | en_US |
dc.identifier.journaltitle | Future Oncology | en_US |
dc.description.pubmeduri | pubmed.ncbi.nlm.nih.gov/32713198/ | en_US |
dc.description.affiliates | Division of Cancer Surgery, Peter MacCallum Centre, Melbourne, Victoria, Australia. | en_US |
dc.description.affiliates | University of Melbourne, Department of Surgery, Austin Hospital, Melbourne, Victoria, Australia. | en_US |
dc.description.affiliates | Department of Surgery, University of Melbourne & Royal Melbourne Hospital, Department of Urology, Melbourne, Victoria, Australia. | en_US |
dc.description.affiliates | Sir Peter MacCallum Dept. of Oncology, University of Melbourne, Melbourne, Victoria, Australia. | en_US |
dc.type.studyortrial | Review | en_US |
dc.type.contenttype | Text | en_US |
Appears in Collections: | UroRenal, Vascular |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.